Ramucirumab is a fully human monoclonal antibody (igg1) developed for the treatment of solid tumors.it is directed against the vascular endothelial growth factor receptor 2 (vegfr2). by binding to vegfr2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (vegf) to vegfr2. vegfr2 is known to mediate the majority of the downstream effects of vegf in angiogenesis.